Core Insights - Minsheng Health announced on August 27 that its main product, the Weikang series, continues to show steady growth, particularly the flagship product, 21 Jinweita Multivitamin Tablets, which has increased both in sales volume and sales value in offline channels [1] Group 1: Product Performance - The 21 Jinweita has a quantity market share of 35.12% in pharmacy terminals, up 3.26% year-on-year, and a value market share of 25.05%, up 5.85% year-on-year, both outperforming the multivitamin market average [1] - Online sales of Weikang products have also seen significant growth through the expansion of sales platforms [1] Group 2: Strategic Focus - Weikang products serve as the company's foundational offerings, and the company plans to continue product expansion and channel deepening to maintain its market position [1] - The company aims to enhance profit margins through increased production, seeking upstream and downstream pricing premiums, and internal refined management [1]
民生健康：25H1公司主力产品维矿系列保持稳健增长